Company Analysis
Sign in

Gain Therapeutics, Inc. (GANX)

Nasdaq: GANX · Pharmaceutical Preparations · Bethesda, MD · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.2
◀ Past 3.7● Present 3.6▶ Future 5.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 26, 2026Mar 27, 2025Mar 26, 2024Mar 23, 2023Mar 25, 2022·
Revenue··55,180140,108164,99428,881
For lenders
Net interest income··494,234375,35712,4953,637
Research and development10,212,78210,791,05811,520,6138,377,2907,164,2292,259,204
General and administrative8,497,9209,559,53410,787,7009,539,8636,826,9381,249,126
Total operating expenses18,710,70220,350,59222,308,31317,917,15313,991,1673,508,330
Operating income-18,710,702-20,350,592-22,253,133-17,777,045-13,826,173-3,479,449
Interest expense····0·
Interest and investment income038,000····
Interest income (expense), net244,394357,096494,234···
Income before income taxes-19,299,981-19,874,376-22,188,245-17,497,762-13,886,598-3,572,296
Income tax expense861,118536,81579,27592,9764,0085,386
Net income including non-controlling interests-20,161,099-20,411,191-22,267,520-17,590,738-13,890,606-3,577,682
Net income-20,161,099-20,411,191-22,267,520-17,590,738-13,890,606-3,577,682
Earnings per share, basic-0.61-0.89-1.71-1.48-1.37-1.33
Earnings per share, diluted-0.61-0.89-1.71-1.48-1.37-1.33
Weighted average shares, basic32,968,33622,881,41513,011,36111,883,36810,165,4042,681,408
Weighted average shares, diluted32,968,33622,881,41513,011,36111,883,36810,165,4042,681,408
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Net interest income interest earned less interest paidus-gaap:InterestIncomeExpenseNet
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseDebt
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeNonoperating
Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton GANX · research, not advice